文献速递肥胖与代谢综合征

体重指数与肥胖相关复杂性多病共存风险:一项观察性多队列研究

Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2022-03-04

该观察性多队列研究汇总两项芬兰队列114 657名成人(1998-2013年入组)数据,并在英国生物银行499 357名成人中重复验证,评估肥胖作为多种常见疾病共同风险因素及其与复杂性多病共存(≥4种共病)的关联。与健康体重相比,肥胖者发生复杂性多病共存的校正HR为12.39(95%CI 9.26-16.58),人群归因分数为55.2%(95%CI 50.9-57.5)。

要点

  • 肥胖与21种非重叠疾病相关,校正后HR均不低于1.50。
  • 肥胖者复杂性多病共存风险显著升高,HR 12.39(95%CI 9.26-16.58)。
  • 超重与复杂性多病共存关联较弱,HR 2.67(95%CI 1.94-3.68)。

核心结论

  • 肥胖与多种且不断增加的疾病负担相关,可能成为多病共存预防的重要靶点,从而避免多靶点预防方案的复杂性。

研究设计与样本

  • 观察性研究,汇总两项芬兰队列(健康与社会支持研究、芬兰公共部门研究)114 657名16-78岁成人(1998-2013年入组)的前瞻性数据,并在英国生物银行499 357名38-73岁成人(2006-10年入组)中重复验证。

主要发现

  • 芬兰队列平均随访12.1年(SD 3.8),英国生物银行队列平均随访11.8年(SD 1.7)。
  • 肥胖与21种非重叠的心代谢、消化、呼吸、神经、肌肉骨骼和感染性疾病相关(经Bonferroni多重检验校正并忽略HR低于1.50的关联)。
  • 与健康体重相比,肥胖者发生至少一种肥胖相关疾病的校正HR为2.83(95%CI 2.74-2.93;PAF 19.9% [95%CI 19.3-20.5]),发生两种疾病为5.17(95%CI 4.84-5.53;PAF 34.4% [95%CI 33.2-35.5]),发生复杂性多病共存为12.39(95%CI 9.26-16.58;PAF 55.2% [95%CI 50.9-57.5])。
  • 健康体重者到75岁时的复杂性多病共存比例,在肥胖者中于55岁时即已观察到;肥胖程度与复杂性多病共存呈剂量-反应关系。
  • 与肥胖相比,超重与复杂性多病共存的关联较弱(HR 2.67,95%CI 1.94-3.68;PAF 13.3% [95%CI 9.6-16.3]);英国生物银行队列观察到相同模式的结果。

关键数值与推荐

  • BMI分类:肥胖≥30.0 kg/m2,超重25.0-29.9 kg/m2,健康体重18.5-24.9 kg/m2,体重不足<18.5 kg/m2。
  • 复杂性多病共存定义为四种或以上共病疾病。
  • 肥胖与至少一种肥胖相关疾病的校正HR为2.83(95%CI 2.74-2.93;PAF 19.9% [95%CI 19.3-20.5])。
  • 肥胖与两种疾病的校正HR为5.17(95%CI 4.84-5.53;PAF 34.4% [95%CI 33.2-35.5])。
  • 肥胖与复杂性多病共存的校正HR为12.39(95%CI 9.26-16.58;PAF 55.2% [95%CI 50.9-57.5])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The accumulation of disparate diseases in complex multimorbidity makes prevention difficult if each disease is targeted separately. We aimed to examine obesity as a shared risk factor for common diseases, determine associations between obesity-related diseases, and examine the role of obesity in the development of complex multimorbidity (four or more comorbid diseases). METHODS: We did an observational study and used pooled prospective data from two Finnish cohort studies (the Health and Social Support Study and the Finnish Public Sector Study) comprising 114 657 adults aged 16-78 years at study entry (1998-2013). A cohort of 499 357 adults (aged 38-73 years at study entry; 2006-10) from the UK Biobank provided replication in an independent population. BMI and clinical characteristics were assessed at baseline. BMIs were categorised as obesity (≥30·0 kg/m2), overweight (25·0-29·9 kg/m2), healthy weight (18·5-24·9 kg/m2), and underweight (<18·5 kg/m2). Via linkage to national health records, participants were followed-up for death and diseases diagnosed according to the International Classification of Diseases 10th Revision (ICD-10). Hazard ratios (HRs) with 95% CIs and population attributable fractions (PAFs) for associations between BMI and multimorbidity were calculated. FINDINGS: Mean follow-up duration was 12·1 years (SD 3·8) in the Finnish cohorts and 11·8 years (1·7) in the UK Biobank cohort. Obesity was associated with 21 non-overlapping cardiometabolic, digestive, respiratory, neurological, musculoskeletal, and infectious diseases after Bonferroni multiple testing adjustment and ignoring HRs of less than 1·50. Compared with healthy weight, the confounder-adjusted HR for obesity was 2·83 (95% CI 2·74-2·93; PAF 19·9% [95% CI 19·3-20·5]) for developing at least one obesity-related disease, 5·17 (4·84-5·53; 34·4% [33·2-35·5]) for two diseases, and 12·39 (9·26-16·58; 55·2% [50·9-57·5]) for complex multimorbidity. The proportion of participants of healthy weight with complex multimorbidity by age 75 years was observed by age 55 years in participants with obesity, and degree of obesity was associated with complex multimorbidity in a dose-response relationship. Compared with obesity, the association between overweight and complex multimorbidity was more modest (HR 2·67, 95% CI 1·94-3·68; PAF 13·3% [95% CI 9·6-16·3]). The same pattern of results was observed in the UK Biobank cohort. INTERPRETATION: Obesity is associated with diverse, increasing disease burdens, and might represent an important target for multimorbidity prevention that avoids the complexities of multitarget preventive regimens. FUNDING: Wellcome Trust, Medical Research Council, National Institute on Aging.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Kivimäki M, Strandberg T, Pentti J, et al. Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol. 2022. PMID: 35248171. doi:10.1016/S2213-8587(22)00033-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。